Lilly(Eli) & Company

Research Lilly(Eli) & Company (LLY) on Bullrun: valuation model: 11.6% overvalued, market cap USD 1.10T, P/E 44.3, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLLY
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal11.6% overvalued
• Market capUSD 1.10T
• P/E44.3
• Dividend yield0.5%
• Financial periodFY2025
• RevenueUSD 65.18B
• Revenue growth44.7%
• Net incomeUSD 20.64B
• Gross margin83.0%

Valuation Snapshot

Bullrun's latest valuation model marks Lilly(Eli) & Company as 11.6% overvalued; latest market cap is USD 1.10T; P/E is 44.3; dividend yield is 0.5%.

About Lilly(Eli) & Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes;

Frequently asked questions

Is Lilly(Eli) & Company overvalued or undervalued?

Bullrun's valuation model currently marks Lilly(Eli) & Company as 11.6% overvalued.

What is Lilly(Eli) & Company's market cap?

Lilly(Eli) & Company's market capitalization is USD 1.10T.

What is Lilly(Eli) & Company's P/E ratio?

Lilly(Eli) & Company's price-to-earnings (P/E) ratio is 44.3.

Does Lilly(Eli) & Company pay a dividend?

Lilly(Eli) & Company has a dividend yield of 0.5%.

What does Lilly(Eli) & Company do?

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.